Elix and University of Vienna sign AI drug discovery pact

Elix and the University of Vienna have formed a joint research agreement to use AI and NMR-based structural biology to speed drug discovery. The project targets hard-to-treat proteins, including intrinsically disordered proteins and cancer-linked epigenetic targets.

Why it matters: - The agreement could help identify drug candidates for targets that traditional discovery methods struggle to reach. - The collaboration combines AI-driven molecular design with atomic-resolution structural data, which may improve hit finding and reduce early-stage trial-and-error. - The project focuses on disease areas with high unmet need, including cancer-related and epigenetic signaling targets.

What happened: - Elix, Inc. and the University of Vienna signed a joint research agreement on July 29, 2026. - The partnership brings together Elix and the research group led by Associate Professor Julien Orts at the University of Vienna. - The companies said the collaboration will advance drug discovery using AI technologies.

The details: - Elix is a Tokyo-based AI drug discovery company. - Elix Discovery™, the company’s integrated platform, uses an intuitive graphical interface to build predictive models for compound profiling. - The platform includes structure generation tools and supports ligand-based drug design and structure-based drug design. - Elix says the platform can propose structures that humans would not conceive. - The University of Vienna group specializes in NMR spectroscopy for atomic-resolution structures, dynamics and biomolecular interactions. - The Orts lab uses methods including INPHARMA for validating small-molecule binding modes and NMR² for automated protein-ligand structure determination. - The lab also uses eNOE distance measurements with 0.1 Å accuracy to resolve protein ensembles. - The joint project aims to design and develop novel compounds against intrinsically disordered proteins and proteins involved in epigenetic signaling and cancer. - The agreement combines Elix’s chemoinformatics and AI-based molecular generation with the Orts group’s structural dynamics and NMR-validated interaction data. - Reference links in the release point to Elix’s prior announcement with PRISM BioLab and Elix’s prior agreement with Tohoku University.

Between the lines: - The deal shows how AI drug discovery is moving from standalone software toward hybrid models that pair machine learning with experimental validation. - The focus on “undruggable” targets suggests both groups are aiming at biologically difficult proteins where conventional screening has struggled. - The University of Vienna’s NMR expertise gives the project a structural biology layer that could make AI-generated candidates more actionable.

What's next: - Elix and the University of Vienna will begin collaborative research under the new agreement. - The teams will work to generate and evaluate compounds for hard-to-drug targets. - The partners did not disclose a timeline for candidate selection, preclinical testing or commercialization.

The bottom line: - Elix is betting that AI plus atomic-level structural biology can open new paths to drug candidates that standard discovery approaches miss.